After months of decline, vitamin prices have stabilized at low levels, leading to subdued market activity. Most buyers have already secured their needs for upcoming quarters. Suppliers remain firm on pricing, prompting a wait-and-see approach across key vitamins.
In partnership with Feed Additive Prices
Vitamin E 50%
The market has become very quiet. After a long period of price decline, the market seems to have stabilised at a low level, after suppliers had started to offer strong resistance against any further decline. That triggered forward contracting among buyers, and since then, it has become relatively quiet. The resistance amongst suppliers to reduce prices further is still there, and one of the main Chinese manufacturers has even increased its price for new business quite significantly. No reaction from the market so far, though. Q4, Q1, and even a portion of Q2 is contracted already.
Vitamin A 1000
Relatively quiet and stable market right now. Although in some regions the tone still feels weak, overall, the prices have stabilised after a long period of decline. Still, most suppliers are either not offering or remain stable/firm on the price. Most buyers have secured their Q1 volume and some even a bit of Q2 and are on the sidelines now to see how the market with evolve further.
Vitamin D3 500
In recent weeks, the market has experienced some activity, and minor price increases due to tight availability, but it has since settled down to a quieter state. FOB China and DDP Europe prices have even been a bit weaker last week, prices in the USA have stayed relatively stable until now. Prices are still significantly higher than they were a year ago. Q4 is largely secured, and a considerable portion of Q1 has also been contracted at this point.
Vitamin B2 80%
The market remains steady with stable prices. Despite a recent small price decline in China, this has not resulted in significant changes in other regions, and the quiet and stable market dynamics have been the same for weeks already. Contracts for Q4 and part of Q1 have already been secured.
D-Calpan
Activity in the market remains sparse, with prices stabilising at low levels. After an extended period of calm, some suppliers have started to probe for new demand, yet buyers seem disinterested in making any moves at this time. With the fourth quarter and a significant share of the first quarter already contracted, the overall market atmosphere continues to be quiet.
Vitamin B3
The market has remained consistently quiet and steady for several weeks. Current market prices continue to be low. Some suppliers are still proactive in seeking to secure longer contracts extending into 2026, which has prompted many buyers to adopt a wait-and-see approach. Contracts for the fourth quarter, first quarter, and part of the second quarter are already in place.
Biotin
The biotin market has been steady and static for a long time already, and no change in market prices has been seen in any region. Prices remain at an all-time low level. Q4 and at least Q1 have been contracted already.
Vitamin C 35% mono
Sellers remain keen to increase the market price and continue to either stop offering or ask for higher prices, but there is no new demand right now. Forward contracts for Q4 and Q1 have been concluded already some time ago at low price levels.
